AstraZeneca pens agentic AI licensing deal with Owkin
AstraZeneca has signed a three-year licensing deal with Owkin to use its agentic AI platform, K Pro, for drug research and competitive intelligence, integrating custom AI agents into its workflows. The partnership follows Owkin’s earlier collaboration with AstraZeneca on an AI tool for pre-screening BRCA mutations in breast cancer patients and aligns with the company’s broader AI-driven strategy for drug development and revenue growth targets.
AstraZeneca has entered a three-year licensing agreement with Owkin to deploy its autonomous AI platform, K Pro, designed to accelerate pharmaceutical research and decision-making. The deal grants AstraZeneca access to Owkin’s AI Scientist platform, which automates data analysis across scientific, clinical, and competitive intelligence domains. Owkin will develop custom biopharma AI agents to streamline AstraZeneca’s research processes, including clinical trial monitoring, recruitment trends, patent filings, and strategic planning. The platform integrates multimodal patient data from over 800 hospitals to support these efforts. The partnership builds on prior collaboration between the companies, including the development of an AI-powered tool for pre-screening BRCA mutations in breast cancer patients. Financial terms of the agreement were not disclosed, but AstraZeneca plans to integrate the tools into its IT infrastructure and decision workflows. Owkin CEO and co-founder Thomas Clozel emphasized the company’s belief in agentic AI as the future of pharmaceutical innovation. This deal reflects a broader industry trend, as major pharmaceutical companies increasingly adopt AI to shorten drug development timelines and enhance operational efficiency. AstraZeneca has previously highlighted AI as central to its goal of reaching $80 billion in revenue by 2030. Recent months have seen other Big Pharma partnerships, including Bristol Myers Squibb’s collaboration with Faro, Novo Nordisk’s and Merck’s enterprise-wide AI deals with OpenAI and Google, and Eli Lilly’s Nvidia supercomputer initiative, Lillypod. Owkin’s K Pro platform is designed to analyze clinical trial activity, recruitment trends, potential outcomes, and patent filings to inform AstraZeneca’s strategic decisions. The company stated that the AI agents will support clinical trial planning and internal decision-making, leveraging vast datasets to drive efficiency. AstraZeneca’s adoption of Owkin’s technology underscores the growing importance of AI in accelerating pharmaceutical innovation and maintaining a competitive edge in drug development.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.